

# ERYTHROMYCIN GEL- erythromycin gel gel

## SOLA Pharmaceuticals

### Erythromycin Topical Gel USP, 2%


### For Dermatologica Use Only-Not for Ophthalmic Use

### Rx Only

### Description

Erythromycin Topical Gel USP, 2% contains erythromycin (3R\*, 4S\*, 5S\*, 6R\*, 7R\*, 9R\*, 11R\*, 12R\*, 13S\*, 14R\*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)- $\beta$ -D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is a macrolide antibiotic produced from a strain of *Saccharopolyspora erythraea* (formerly *Streptomyces erythreus*). It is a base and readily forms salts with acids.

Chemically, erythromycin is C<sub>37</sub>H<sub>67</sub>NO<sub>13</sub>. . It has the following structural formula:



Erythromycin	R <sub>1</sub>	R <sub>2</sub>
A	OH	OCH <sub>3</sub>
B	H	OCH <sub>3</sub>
C	OH	OH

Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practically odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such as alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polar solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solvents such as hexane. It is very poorly soluble in water.

Each gram of Erythromycin Topical Gel USP, 2% (clear, colorless, gel) contains 20 mg of erythromycin USP in a vehicle consisting of alcohol (92% v/v) and hydroxypropyl cellulose.

### Clinical Pharmacology

The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known;

however, the effect appears to be due in part to the antibacterial activity of the drug.

## **Microbiology**

Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin.

## **Indication and Usage**

Erythromycin Topical Gel USP, 2% is indicated for the topical treatment of acne vulgaris.

## **Contraindications**

Erythromycin Topical Gel USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

## **Warnings**

**Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.**

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is one primary cause of "antibiotic-associated colitis".

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against *C. difficile* colitis.

## **Precautions**

### **General -**

For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents.

The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes.

## **Information for Patients**

Patients using Erythromycin Topical Gel USP, 2% should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact

with the eyes, nose, mouth, and all mucous membranes.

2.This medication should not be used for any disorder other than that for which it was prescribed.

3.Patients should not use any other topical acne medication unless otherwise directed by their physician.

4.Patients should report to their physician any signs of local adverse reactions.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility -**

No animal studies have been performed to evaluate carcinogenic and mutagenic potential, or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.

### **Pregnancy:**

Teratogenic Effects:

*Pregnancy Category B -*

There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.

### **Nursing Women -**

It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

### **Pediatric Use -**

Safety and effectiveness in pediatric patients have not been established.

KEEP OUT OF REACH OF CHILDREN.

### **Adverse Reactions**

In controlled clinical trials, the incidence of burning associated with Erythromycin Topical Gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Teligent Pharma, Inc., at 1-856-697-1441 and/or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### **Dosage and Administration**

Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d.dosing.

### **How Supplied**

Erythromycin Topical Gel USP, 2% is available as follows:

60 g sealed metal tube (NDC 70512-035-60)

Manufactured for:

Sola Pharmaceuticals

Baton Rouge, LA 70809

Rev. 10/2017

### Storage

Note - **FLAMMABLE. Keep away from heat and flame.** Store and dispense in original container. Keep tube tightly closed. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

### Package Label

PRINCIPAL DISPLAY PANEL - 60g Tube Carton

NDC 70512-035-60

Erythromycin Topical Gel USP, 2%

For Topical Use Only.

Not For Ophthalmic Use.

Net Wt. 60g

Rx Only

**Description:** Erythromycin Topical Gel, 2% contains erythromycin USP (20mg/g) in a vehicle consisting of alcohol and hydroxypropyl cellulose.

**Dosage:** Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. Spread the medication lightly rather than rubbing it in. Hands should be washed after application. See accompanying Package Insert for complete prescribing information.

**KEEP OUT OF REACH OF CHILDREN.**

**NOTE — FLAMMABLE. KEEP AWAY FROM HEAT AND FLAME.**

Keep tube tightly closed. Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature].

To open: Use cap to puncture seal.



Manufactured for:  
SOLA Pharmaceuticals  
Baton Rouge, LA 70809  
C101071 Rev. 01/2019



NDC 70512-035-60

**Erythromycin Topical Gel USP, 2%**

**For Topical Use Only  
Not for Ophthalmic Use**

**Net Wt 60 g**

**Rx only**



## ERYTHROMYCIN GEL

erythromycin gel gel

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70512-035
Route of Administration	TOPICAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ERYTHROMYCIN (UNII: 63937KV33D) (ERYTHROMYCIN - UNII:63937KV33D)	ERYTHROMYCIN	20 mg in 1 g

### Inactive Ingredients

Ingredient Name	Strength
ALCOHOL (UNII: 3K9958V90M)	
HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70512-035-60	1 in 1 CARTON	02/04/2019	
1		60 g in 1 TUBE; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA208154	02/04/2019	

**Labeler** - SOLA Pharmaceuticals (080121345)

## Establishment

Name	Address	ID/FEI	Business Operations
Teligent Pharma, Inc.		011036910	manufacture(70512-035)

Revised: 10/2019

SOLA Pharmaceuticals